Clear Harbor Asset Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Clear Harbor Asset Management’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-145,400	Closed	-$34.9K	–	423
2025 Q2	$34.9K	Sell	145,400 -95,325	-40%	-$25.4K	﹤0.01%	406
2025 Q1	$47.4K	Buy	240,725 +222,200	+1,199%	+$115K	﹤0.01%	400
2024 Q4	$9.98K	Buy	+18,525	New	+$13.5K	﹤0.01%	391

Other funds holding ADAP

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

Clear Harbor Asset Management's ADAP Position: Q3 2025 in Review

Clear Harbor Asset Management sold out of Adaptimmune Therapeutics (ADAP) in Q3 2025, closing a stake of 145,400 shares — an estimated $34.9K sold.

Clear Harbor Asset Management first reported a position in ADAP in Q4 2024 and held it in 3 quarters. The position peaked at $47.4K in Q1 2025. 55 funds tracked by Wall St. Rank hold ADAP as of Q3 2025.

Clear Harbor Asset Management reported no remaining Adaptimmune Therapeutics position as of Q3 2025 after selling out during the quarter.
Clear Harbor Asset Management sold 145,400 Adaptimmune Therapeutics shares in Q3 2025, an estimated $34.9K.
Clear Harbor Asset Management first reported a position in Adaptimmune Therapeutics in Q4 2024 and held it in 3 quarters.
Clear Harbor Asset Management's Adaptimmune Therapeutics position peaked at $47.4K in Q1 2025.
55 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2025.

Based on Clear Harbor Asset Management's 13F filing for Q3 2025, filed 23 Oct 2025.